|ABCA7 (E7O5A) Rabbit mAb 32942||20 µl||
||M R||235||Rabbit IgG|
|SORL1 (D8D4G) Rabbit mAb 79322||20 µl||
||H M||250||Rabbit IgG|
|BIN1 (E4A1P) Rabbit mAb 51844||20 µl||
||H M||45-80||Rabbit IgG|
|EphA1 (D6V7I) Rabbit mAb 90673||20 µl||
||H M||130||Rabbit IgG|
|MEF2C (D80C1) XP® Rabbit mAb 5030||20 µl||
||H M||50-60||Rabbit IgG|
|Pyk2 (5E2) Mouse mAb 3480||20 µl||
||H M||116||Mouse IgG2a|
|TREM2 (E6T1P) Rabbit mAb (Amino-terminal Antigen) 61788||20 µl||
|TREM2 (E7P8J) Rabbit mAb (Carboxy-terminal Antigen) 76765||20 µl||
||M||11, 28||Rabbit IgG|
|ApoE (E7X2A) Rabbit mAb 49285||20 µl||
|Anti-rabbit IgG, HRP-linked Antibody 7074||100 µl||
Monoclonal antibodies are produced by immunizing animals with synthetic peptides corresponding to residues surrounding Asp26 of mouse ApoE protein, Val266 of human BIN1 protein, Glu267 of human SORL1 protein, Met182 of human MEF2 protein, Gly215 of mouse TREM2 protein, residues near the amino-terminus of mouse TREM2 protein, and a recombinant protein fragment specific to the extracellular domain of human EphA1 protein. Pyk2 (5E2) Mouse mAb is produced by immunizing animals with a GST-Pyk2 fusion protein containing residues surrounding the carboxy-terminal of human Pyk2 protein.
Alzheimer's Disease (AD) is the leading cause of dementia worldwide. Clinically, it is characterized by the presence of extracellular amyloid plaques and intracellular neurofibrillary tangles, which result in neuronal dysfunction and cell death (1). Genome-wide association studies (GWAS) have identified a cohort of risk genes associated with late-onset AD (LOAD), including, but not limited to, APOE, BIN1, SORL1, TREM2, EphA1, MEF2C, ABCA7, and PTK2B (2).
APOE has three allele variants; ApoE2, ApoE3, and ApoE4; with ApoE4 associated with an increased risk of AD. Evidence suggests that this risk occurs through promotion of amyloid-beta plaque aggregation (1). ApoE4 is also associated with impaired microglial response, lipid transport, synaptic integrity and plasticity, glucose metabolism, and cerebrovascular integrity (3). Mutations in BIN1, primarily involved in endocytosis and maintaining cytoskeletal integrity in the brain, are suggested to play a role in the aggravation of tau pathology (4,5). Increased levels of BIN1 have been seen in AD postmortem brain tissue (5). SORL1 expression is decreased in the brain of AD patients (6). Studies have demonstrated a role for SORL1 as a neuronal sorting receptor that binds amyloid precursor protein (APP) and regulates its trafficking and proteolytic processing, thus regulating β-amyloid (Aβ) peptide production (7). The triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune receptor that is expressed on the cell surface of microglia, macrophages, osteoclasts, and immature dendritic cells (8). Research studies using AD mouse models indicate that deficiency and haploinsufficiency of TREM2 can lead to increased Aβ accumulation due to dysfunctional microglia response (9). EphA1 is a member of the ephrin family of receptor tyrosine kinases responsible for regulating cell morphology and motility (10). In the central nervous system (CNS), EphA1 plays a role in synaptic plasticity and axon guidance (11). EphA1 is involved in inflammatory signaling pathways (12), which may mean it plays a role in regulation of neuroinflammatory processes in AD (13). ATP-binding cassette sub-family A member 7 (ABCA7) functions to regulate phospholipid and cholesterol homeostasis in the CNS (14,15). ABCA7 dysfunction may contribute directly to AD pathogenesis by accelerating Aβ production and/or altering microglia-dependent phagocytosis of Aβ (16-18). MEF2C is a member of the myocyte enhancer factor 2 (MEF2) family of transcription factors shown to play a role in learning and memory formation through regulation of synaptic plasticity (19). Studies have shown that MEF2C may play a role in age-related microglial activation through IFN-I associated MEF2C deregulation (20,21). MEF2C may also act as a modulator for APP proteolytic processing of Aβ (22,23). Protein tyrosine kinase, Pyk2, encoded by the PTK2B gene, is a non-receptor tyrosine kinase highly expressed in neurons with implications in synaptic plasticity (24,25). In mouse models, knockout of Pyk2 impairs hippocampal-dependent memory and long-term potentiation (24). Overexpression of Pyk2 has been shown to protect neurons against Aβ42-induced synaptotoxicity (26). Pyk2 may also act as a kinase for tau phosphorylation and has been implicated as a modulator of tau toxicity (27,28).
Explore pathways related to this product.
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.